{"entity":{"id":"nct06237881","kind":"trial","name":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of KSQ-001EX run by M.D. Anderson Cancer Center, active, not recruiting.","summary":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06237881 by M.D. Anderson Cancer Center, with 15 participants planned, started 2024-01-31, primary completion expected 2027-01-01. Conditions recorded: Advanced Solid Tumor, Melanoma, Lung Neoplasms, Head and Neck Neoplasms. Interventions recorded: KSQ-001EX, Interleukin-2, Cyclophosphamide, Fludarabine.","status":"active","asOf":"2026-11-04","links":[{"label":"ClinicalTrials.gov NCT06237881","url":"https://clinicaltrials.gov/study/NCT06237881"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["ksq-001ex"],"companies":["ksq-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06237881","phase":"1/2","setting":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","sponsor":"M.D. Anderson Cancer Center","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06237881/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"ksq-001ex","kind":"drug","name":"KSQ-001EX","route":"/drugs/ksq-001ex/"}],"company":[{"id":"ksq-therapeutics","kind":"company","name":"KSQ Therapeutics","route":"/companies/ksq-therapeutics/"}]}}